- Home
- MGRM vs IGMS Comparison
MGRM vs IGMS Comparison
Compare MGRM & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- IGMS
- Stock Information
- Founded
- MGRM 2016
- IGMS 1993
- Country
- MGRM United States
- IGMS United States
- Employees
- MGRM N/A
- IGMS N/A
- Industry
- MGRM Medical/Dental Instruments
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- IGMS Health Care
- Exchange
- MGRM Nasdaq
- IGMS Nasdaq
- Market Cap
- MGRM 85.1M
- IGMS 82.1M
- IPO Year
- MGRM N/A
- IGMS 2019
- Fundamental
- Price
- MGRM $2.32
- IGMS $1.38
- Analyst Decision
- MGRM Strong Buy
- IGMS Hold
- Analyst Count
- MGRM 1
- IGMS 8
- Target Price
- MGRM $4.00
- IGMS $6.14
- AVG Volume (30 Days)
- MGRM 34.4K
- IGMS 368.0K
- Earning Date
- MGRM 03-14-2025
- IGMS 03-06-2025
- Dividend Yield
- MGRM N/A
- IGMS N/A
- EPS Growth
- MGRM N/A
- IGMS N/A
- EPS
- MGRM N/A
- IGMS N/A
- Revenue
- MGRM $364,999.00
- IGMS $2,918,000.00
- Revenue This Year
- MGRM N/A
- IGMS $26.85
- Revenue Next Year
- MGRM N/A
- IGMS $125.17
- P/E Ratio
- MGRM N/A
- IGMS N/A
- Revenue Growth
- MGRM N/A
- IGMS 57.64
- 52 Week Low
- MGRM $1.53
- IGMS $1.26
- 52 Week High
- MGRM $4.90
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- MGRM 33.75
- IGMS 26.21
- Support Level
- MGRM $2.32
- IGMS $1.26
- Resistance Level
- MGRM $2.57
- IGMS $1.54
- Average True Range (ATR)
- MGRM 0.17
- IGMS 0.13
- MACD
- MGRM -0.06
- IGMS 0.22
- Stochastic Oscillator
- MGRM 0.00
- IGMS 29.27
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.